6533b82efe1ef96bd1293d05
RESEARCH PRODUCT
Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.
Antonino NastasiTeresa FascianaGiovanna PesaventoRoberto Degl’innocentiTamara BrunelliAurora AleoCaterina MamminaCelestino Bonurasubject
Microbiology (medical)CarbapenemSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeClone (cell biology)Drug resistanceMicrobial Sensitivity TestsSettore MED/42 - Igiene Generale E ApplicataHospitals Generalbeta-LactamsMicrobiologyDrug Resistance BacterialmedicineHumansPharmacology (medical)General hospitalhospitalSequence (medicine)Cross InfectionbiologyGeneral Medicinebiology.organism_classificationST101Anti-Bacterial AgentsKlebsiella InfectionsImipenemKlebsiella pneumoniaeInfectious DiseasesCarbapenemsItalymedicine.drugdescription
Klebsiella pneumoniae is one of the most common multidrug-resistant (MDR) Gram-negative organisms worldwide, responsible for high morbidity and mortality both in hospitals and alternative healthcare settings. Recently, increasing use of carbapenems has promoted the emergence and dissemination of carbapenem-non-susceptible MDR K. pneumoniae strains. All of the CNSKP strains isolated between January 2009 and December 2011 in the General Hospital of Prato (Prato, Italy) were studied. Our findings indicate that, unlike previously reported by other authors from different regions of Italy, K. pneumoniae producing KPC-2 and belonging to ST101 have been established in the area of Prato, Tuscany, Italy. This study confirms the previously reported involvement of multiple clones of K. pneumoniae in the spread of carbapenem resistance in Italy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-02-15 | International journal of antimicrobial agents |